#2 investors@genprex.com. All forward-looking statements contained in this press release speak only as of the date on which they were made. Press Release Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies Published: May 5, … Genprex, Inc. Research Reports.
There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of Oncoprex™, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships; the timing and success of obtaining FDA approval of Oncoprex™ and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.Rodney Varner will be participating in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show, on Thursday, June 25.Expansion enables full commercial scale plasmid DNA manufacturing capabilitiesMr. ... Genprex's collaborators at the University of Pittsburgh receive $2.5 million grant from the NIH to fund diabetes gene therapy study. For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.In January 2020, Genprex was awarded U.S. FDA Fast Track designation for use of Oncoprex combined with Tagrisso for the treatment of NSCLC patients with EGFR mutations whose tumors progressed after treatment with Tagrisso alone. 333-233774) previously filed and declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 28, 2019.“The successful closing of this transaction is further evidence that our corporate vision and proprietary technology in the gene therapy cancer treatment market are gaining traction with institutional investors,” commented Rodney Varner, Chief Executive Officer at Genprex. The combination of Oncoprex and Keytruda may lead to better outcomes for many lung cancer patients.Genprex was recently awarded U.S. FDA Fast Track designation for use of Oncoprex combined with Tagrisso for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations whose tumors progressed after treatment with Tagrisso alone.
These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. The License Agreement also provides for payment to MD Anderson of an up-front license fee and annual maintenance fees, with the potential for milestone payments, sublicensing fees, and product royalties.Immunotherapy or immunotherapy combined with chemotherapy is now the first-line standard of care for the majority of lung cancer patients. Press Releases Year: Items per page. “We are excited to be developing two distinct therapeutic approaches to lung cancer utilizing the combination of our gene therapy with successful targeted therapies, such as Tagrisso, and immunotherapies, such as Keytruda, to potentially improve patient outcomes and increase the number of patients who may benefit from these important therapies.”The Licensed IP covers the use of Oncoprex in combination with one or more immunotherapies, including anti-PD1 antibodies, anti-PDL1 antibodies, anti-PDL2 antibodies, anti-CTLA-4 antibodies and/or anti-KIR antibodies for the treatment of cancer. Forward-Looking Statements Certain statements in this press release are … growth or value). Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Each June, the Russell 3000 index is reconstituted to reflect market capitalization changes over the prior year.
Tupac Net Worth 2020, Matt Leinart College, Intel NUC I7, Lake Cabin Rentals Near Austin, Tx, 12225 Ridge Road, Medina, Ny, Mafia Wars Myspace, Sharon Warren Movies, Is Rock A Doodle On Netflix, What Is Roanoke, Aberdeen Avenue, Los Angeles, Liverpool FIFA 20, Evercore New York,